Pharmamarketeer

Pharmazz begins patient dosing in phase 3 study of sovateltide to treat acute cerebral ischemic stroke

Sovateltide

Pharmazz, Inc, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients in critical care, announced the initiation of dosing in its pivotal, phase 3 clinical trial evaluating sovateltide for the treatment of acute cerebral ischemic stroke

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl